Currently available treatments for anemia in patients receiving anticancer treatments include blood transfusions, iron supplementation, and erythropoiesis-stimulating agents (ESAs), like recombinant EPO (rhEPO) and darbepoetin-α. This evidence concerns the gene EPO and anemia.